High prevalence of bronchial hyperresponsiveness and asthma in ice hockey players

J.D. Leuppi*, M. Kuhn*, C. Comminot, W.H. Reinhart*

ABSTRACT: The prevalence of asthma was studied in an ice hockey team compared with both a floor ball team and the Swiss population.

Lung function, bronchial hyperresponsiveness to methacholine, asthma symptoms and exercise-induced asthma were measured in a cross-sectional prospective study.

A positive response to the methacholine bronchial provocation test was found in 34.6% of the ice hockey players and 20.8% of the floor ball players (Swiss population 16.4%). The provocative dose causing a 20% fall in the forced expiratory volume in one second (PD20) was significantly lower in ice hockey players than in floor ball players, but there was no significant difference in the dose-response slopes between the two groups. Asthma was diagnosed in 19.2% of the ice hockey players and in 4.2% of the floor ball players (Swiss population 6.8%), whereas exercise-induced asthma was found in 11.5% of the ice hockey players and in 4.2% of the floor ball players.

In conclusion, asthma and bronchial hyperresponsiveness seemed to be more common in ice hockey players than in floor ball players and in the Swiss population. Sustained exercise at lower temperatures may be a risk factor for the higher prevalence of asthma and bronchial hyperresponsiveness, as well as the increased severity of bronchial hyperresponsiveness, particularly in ice hockey players.


Asthma and exercise-induced asthma are not uncommon in either the general population or trained athletes [1]. A prevalence of 16.4% for bronchial hyperresponsiveness [2] and of 6.8% for asthma was found for the general Swiss population in the Swiss study on air pollution and lung diseases in adults (SAPALDIA study) [3]. The prevalence of exercise-induced asthma in Swiss athletes was estimated to be 4.25% [4]. In 1993 Larsson et al. [5] reported a high prevalence of asthma in Swedish cross-country skiers. This sport is performed at low temperatures, often below -10°C. The pathophysiological mechanism responsible for exercise-induced asthma is probably evaporative water loss from the airway mucosa [6] leading to irritation by local airway hyperosmolarity. Inhaling large amounts of cold air triggers bronchoconstriction in asthmatic subjects [7].

Ice hockey players may be at increased risk for asthma or exercise-induced asthma because they exercise or play intensively in cold air (5–10°C), albeit not as cold as for cross-country skiers. Therefore, professionally coached, elite ice hockey players were studied and compared with elite floor ball players and the general Swiss population. Clinical symptoms of asthma, lung function and bronchial hyperresponsiveness (methacholine and exercise-induced challenge) were examined.

Subjects and methods

Twenty-six elite ice hockey players (Ice Hockey Club Chur) and 24 elite floor ball players of the Swiss champion floor ball team (Rot-Weiss Chur) were invited to participate in the study. All gave written, informed consent for the study, which had been approved by the local Ethical Committee. The study was carried out in August and September 1996. The ice hockey players were on average 24 (18–35) yrs old and the floor ball players 20 (17–29) yrs old. All subjects were instructed to avoid any medication, including antihistaminic drugs, for at least 48 h before the study.

In order to identify subjects with a history of asthma or atopic diseases all players were asked to complete a questionnaire including 22 questions on personal history of allergy and smoking habits, which had been part of the validated SAPALDIA questionnaire [8]. Asthma was assumed to be present when positive answers were given to both of the following questions: “Have you ever had asthma?” and “Was this confirmed by your doctor?” Questionnaires were checked and discussed with each subject.

Forced expiratory volume in one second (FEV1) and vital capacity (VC) were measured in the hospital with a spirometer (SensorMedics®, Gambro AG, Switzerland). The FEV1 recorded was the best value of three measurements. In addition, slow VC measurements were undertaken and the highest values of three forced and three slow expirations were recorded [9].

Bronchial hyperresponsiveness was assessed with a methacholine challenge test, following the methodology used by the German working group on bronchial provocation test [10] with the help of a jet nebulizer (Pari Provent®; Labhardt AG, Switzerland) with an output of 5.0

Keywords: Asthma bronchial hyperresponsiveness floor ball ice hockey

Received: July 11 1997
Accepted after revision March 15 1998

Supported by Bündner Liga für Lungenkrankheiten und Tuberkulose and the Wilhelm Doerenkamp Foundation.

*Dept of Internal Medicine, Kantonsspital, Chur, Switzerland. Team Physician, Chur, Switzerland.
L.min⁻¹. The jet nebulizer generates droplets with a median mass aerodynamic diameter of 3.6 µm and 65% of the droplets are <5 µm. Each of the increasing doses of methacholine (100, 200, 400, 500 and 1000 µg) was inhaled from a reservoir bag containing the given dose of methacholine within 5–10 L of air at a respiratory rate of 15 breaths.min⁻¹ during 1 min. Measurements of FEV₁ were performed with a spirometer, beginning 1 min after inhalation. The interval between each dose was 2 min. The dose of methacholine that produced a 20% decrease in FEV₁ (PD₂₀) [11, 12]. The challenge test was regarded as positive when PD₂₀ was <2 mg, which represents an arbitrary cut-off point close to that of 1.5 mg (7.8 µmol) used by YAN et al. [13]. PD₂₀ was logarithmically analysed as geometric mean values. A dose-response slope was calculated for all subjects as the percentage fall in FEV₁ at last dose divided by the total dose administered [14].

The exercise challenge was an 8 min, standardized, free-running or free-skating test in either the gymnastics hall (floor ball players) or the ice hall (ice hockey players) [15]. All subjects had to reach >80% of their predicted maximal cardiac frequency (fC >160 beats.min⁻¹). Spirometry was performed with four portable spirometers (Spirovit SP-1®, Schiller AG, Switzerland), which were calibrated before each session with a 2 L air syringe. The spirometric measurements were made before running or skating and 0, 5, 10, 20 and 30 min after the exercise test, respectively. For the purpose of the study, exercise-induced bronchospasm (EIB) was defined as a fall >10% in FEV₁ compared with pre-exercise values [12, 15, 16]. Subjects were asked about their symptoms after the run, which included chest tightness, difficulty in breathing and/or squeaky or whistling chest.

Asthma was defined as bronchial hyperresponsiveness plus positive answers to the two cardinal questions of the questionnaire (see above).

For statistical analysis, StatView 4.0 software (Abacus Inc, Berkeley, CA, USA) was used on an Apple Macintosh SE/30. Besides descriptive statistics, Pearson's chi-squared test was used for the comparison between groups and one-way analysis of variance (ANOVA) for two-category data with Fisher's t-test for significance. All p-values were two tailed and p<0.05 was interpreted as statistically significant.

**Results**

There was no significant difference in the prevalence of atopy measured by questionnaire. Both teams had 10 players with atopy (42% in ice hockey players and 38% in floor ball players).

No significant difference was observed in the lung function with regard to VC and FEV₁ between ice hockey and floor ball players. Percentage predicted (±SD) for VC in the ice hockey players and floor ball players was 108 (±9) and 106 (±13), respectively, and for FEV₁ was 107 (±10) and 102 (±11), respectively.

Data on bronchial hyperresponsiveness are given in table 1. Ice hockey players had an increased bronchial hyperresponsiveness compared with floor ball players and the general Swiss population (SAPALDIA). Nine of the 26 ice hockey players (34.6%) and five of the 24 floor ball players (20.8%) showed a positive methacholine challenge test (p<0.05). The PD₂₀ was significantly lower in ice hockey players than in floor ball players (geometric mean values 0.52 mg versus 1.64 mg; p=0.001), but there was no significant difference in the dose-response slopes.

Asthma, as defined by the study criteria, tended to be more prevalent in ice hockey players than in floor ball players (absolute values: 5/26 and 1/24, respectively, not significant (NS); relative values: 19.2% and 4.1%, p<0.05). Physician-diagnosed asthma was reported by five of the 26 ice hockey players and by three of the 24 floor ball players. One of the five ice hockey players and two of the three floor ball players had no bronchial hyperresponsiveness and thus did not have asthma by our criteria (table 2). Four of the five asthmatic ice hockey players were taking salbutamol regularly, compared with none of the floor ball players. No players in either team inhaled steroids regularly. Bronchial hyperresponsiveness without airway symptoms (wheezing, breathlessness and chest tightness) was observed in four ice hockey players and in four floor ball players.

An EIB was found following the 8 min, standardized, free-running or free-skating challenge in three of the 26 ice hockey players and in one of the 24 floor ball players.

**Table 1. Methacholine provocation test**

<table>
<thead>
<tr>
<th></th>
<th>Floor ball players</th>
<th>Ice hockey players</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive challenge test PD₂₀ &lt;2 mg</td>
<td>5 (20.8%)</td>
<td>9 (34.6%)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Δ%FEV₁</td>
<td>75±1</td>
<td>69±10</td>
<td>NS</td>
</tr>
<tr>
<td>PD₂₀ mg*</td>
<td>1.64±0.40</td>
<td>0.52±0.33</td>
<td>0.001</td>
</tr>
<tr>
<td>Dose-response slope %</td>
<td>47.8±14.5</td>
<td>557±1147</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are means±SD. PD₂₀: provocative dose causing a 20% fall in the forced expiratory volume in one second (FEV₁). *: methacholine dose at which FEV₁ decreased by 20%; five and nine subjects, respectively. #: geometric mean. ‡: percentage fall in FEV₁ at the last dose divided by the total dose administered. **: nonsignificant.

**Table 2. Prevalence and characteristics of asthma**

<table>
<thead>
<tr>
<th></th>
<th>Floor ball players</th>
<th>Ice hockey players</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma bronchiale</td>
<td>1 (4)</td>
<td>5 (19)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Physician-diagnosed asthma</td>
<td>1 (4)</td>
<td>4 (15)</td>
<td>NS</td>
</tr>
<tr>
<td>with bronchial hyperresponsiveness</td>
<td>2 (8)</td>
<td>1 (4)</td>
<td>NS</td>
</tr>
<tr>
<td>Regular inhalation of β₂-agonists</td>
<td>0</td>
<td>4 (15)</td>
<td>NS</td>
</tr>
<tr>
<td>Regular inhalation of steroids</td>
<td>0</td>
<td>0</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS: nonsignificant.
(8). The three ice hockey players as well as the one floor ball player who suffered an exercise-induced bronchospasm also complained of chest tightness or a squeaky or whistling chest. Three of the 26 ice hockey players and none of the floor ball players were smokers. None of the asthmatics were smokers.

Discussion

This study shows that bronchial hyperresponsiveness, asthma and exercise-induced asthma occur more frequently in ice hockey players than in floor ball players. Whereas the data of the floor ball players were similar to those found in the general Swiss population [3], ice hockey players had a 1.7-fold increased incidence of bronchial hyperresponsiveness to methacholine compared with floor ball players, a 4.6-fold increase in asthma and a 2.7-fold increase in exercise-induced asthma.

A greater proportion of subjects with increased bronchial hyperresponsiveness to methacholine were ice hockey players and their PD20 was significantly lower than in floor ball players, but there was no significant difference in the dose-response slopes. Therefore, the results suggest that the severity of bronchial hyperresponsiveness was increased in ice hockey players compared with floor ball players, but the study was limited by the small sample size and the relatively low doses of methacholine used in the bronchial challenge.

It is very likely that cold air caused the increased prevalence of asthma and bronchial hyperresponsiveness in ice hockey players. Although selection bias cannot be excluded completely, it seems rather unlikely, for instance, that for an unknown reason individuals hyperreactive to cold air who complain of chest tightness or a squeaky or whistling chest. Three of the 26 ice hockey players and none of the floor ball players coughed at the end of the exercise challenge, but all of the three ice hockey players, as well as the one floor ball player who suffered on an exercise-induced bronchospasm, also complained about chest tightness or squeaky or whistling chest. It is likely that many athletes at all levels of competition suffer from unrecognized asthma and exercise-induced asthma [24]. Coaches, trainers and team physicians should be made aware of the diversity of symptoms and should look for asthma as part of the screening process so that athletes receive appropriate treatment [26, 27].

Four of the 25 ice hockey players used antiasthmatic drugs (Salbutamol, on an irregular basis), whereas none of the floor ball players used drugs. No asthmatic players were treated with inhaled corticosteroids. A Dutch trial with long-term therapy with inhaled budesonide in 55 children with exercise-induced asthma showed a reduction in the incidence of exercise-induced asthma by 33% and a reduction in the severity by 50% [28]. Asthma and exercise-induced asthma are not only underdiagnosed but also undertreated. Performance may be limited by asthma or exercise-induced asthma. With effective screening programmes athletes could be treated early in life and participate more fully in their sports.

Acknowledgements: The authors thank M. Maag for her expert technical help, W. Brunner and S. Downs for the revision of the manuscript and Schiller AG, Switzerland, for the portable spirometers.

References


